Sangamo showcases Fabry progress at WORLDSymposium™


Presentation: A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice

Kathleen E. Meyer, Sangamo Therapeutics

  • Platform Presentation: Thursday, February 8, 2024 – 8:00am PT
  • Poster Session: Thursday, February 8, 2024 – 3-5pm PT (Poster: 224)

Download PDF